NLRP3 and heart failure: For instance, dapansutrile, a selective NLRP3 inflammasome inhibitor, has demonstrated both safety and efficacy in reducing joint pain and exhibited great potential in treating heart failure in a phase 1B trial (Klück et al., 2020; Wohlford et al., 2020).